Zydus receives approval for Risperidone Tablets

Ahmedabad, 20 October, 2008

Zydus Cadila has received an approval from the USFDA to market Risperidone Tablets 0.25, 05, 1, 2, 3 and 4 mg. Risperidone falls in the CNS segment and the estimated sales as per NDC was USD 2.1 billion in 2007.

The group now has 41 approvals and has so far filed 79 ANDAs since the commencement of filing process in FY 2003-04.
